Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
LPCN
vs
S&P 500
LPCN
S&P 500
Over the past 12 months, LPCN has underperformed S&P 500, delivering a return of -45% compared to S&P 500's +12% growth.
Stocks Performance
LPCN vs S&P 500
Performance Gap
LPCN vs S&P 500
Create a free account · No card needed
Performance By Year
LPCN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Lipocine Inc
Glance View
Lipocine Inc. is a clinical-stage pharmaceutical company that develops oral medicines, mostly for hormone-related conditions. Its core idea is to take drugs that are hard to give by mouth, reformulate them with its delivery technology, and turn them into easier-to-use pills or capsules. The company’s work has focused on treatments such as testosterone replacement and therapies for women’s health and liver-related disorders. Lipocine does not make broad consumer products. It makes money by advancing drug candidates through development and, if a program succeeds, by partnering with larger drug companies that can handle late-stage development, manufacturing, and commercialization. In that model, Lipocine can receive upfront payments, milestone payments, and royalties tied to sales. Its customers are not patients directly, but pharmaceutical partners, regulators, and eventually physicians and patients who use the approved medicines. What makes Lipocine different is its focus on turning familiar hormones and other compounds into oral treatments that may be more convenient than injections, gels, or patches. That puts the company in a niche part of drug development: it is less about selling a broad drug portfolio and more about creating delivery-enabled versions of known medicines that could fit into everyday prescribing habits.
Create a free account · No card needed
